BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35957546)

  • 1. Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment.
    Park SJ; Hahn YS
    Clin Mol Hepatol; 2023 Jan; 29(1):65-76. PubMed ID: 35957546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.
    Amaddeo G; Nguyen CT; Maillé P; Mulé S; Luciani A; Machou C; Rodrigues A; Regnault H; Mallat A; Laurent A; Lafdil F; Hézode C; Pawlotsky JM; Calderaro J
    Liver Int; 2020 Jan; 40(1):74-82. PubMed ID: 31444947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis.
    Khatun M; Ray RB
    Cells; 2019 Oct; 8(10):. PubMed ID: 31615075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
    Ramadan HK; Badr G; Ramadan NK; Sayed A
    Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.
    Bandiera S; Pernot S; El Saghire H; Durand SC; Thumann C; Crouchet E; Ye T; Fofana I; Oudot MA; Barths J; Schuster C; Pessaux P; Heim MH; Baumert TF; Zeisel MB
    J Virol; 2016 Jul; 90(14):6387-6400. PubMed ID: 27147737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma.
    Cevik O; Li D; Baljinnyam E; Manvar D; Pimenta EM; Waris G; Barnes BJ; Kaushik-Basu N
    J Biol Chem; 2017 Dec; 292(52):21676-21689. PubMed ID: 29079574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
    Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
    Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during hepatitis C virus infection.
    Cobb DA; Kim OK; Golden-Mason L; Rosen HR; Hahn YS
    Hepatology; 2018 Jan; 67(1):71-85. PubMed ID: 28749570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection Induces Transforming Growth Factor β1 Production through Glucose-Regulated Protein 94.
    Jee MH; Hong KY; Park JH; Lee JS; Kim HS; Lee SH; Jang SK
    J Virol; 2015 Dec; 90(6):3044-55. PubMed ID: 26719248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.
    Virzì A; Roca Suarez AA; Baumert TF; Lupberger J
    Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31501266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals.
    Li S; Mizukoshi E; Kawaguchi K; Miura M; Nishino M; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Honda M; Kaneko S
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment.
    Ferreira J; Oliveira M; Bicho M; Serejo F
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC.
    Park SJ; Hahn YS
    Rev Infect; 2010 Jul; 1(3):151-157. PubMed ID: 24688607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
    Hartlage AS; Walker CM; Kapoor A
    J Virol; 2020 May; 94(10):. PubMed ID: 32102885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of the Regulatory T lymphocytes in hepatitis C fibrosis progression].
    Delhem N; Cottrez F; Carpentier A; Miroux C; Moralès O; François V; Groux H; Auriault C; Pancré V
    Bull Cancer; 2008 Nov; 95(11):1029-38. PubMed ID: 19036674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections.
    Patra T; Sasaki R; Meyer K; Ray RB; Ray R
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
    J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.